Javascript must be enabled to continue!
SUN-135 Characterization of Transcription Factor Immunostaining and Null Cell Adenoma Status in Hormone Negative Pituitary Adenomas
View through CrossRef
Abstract
Introduction: Since the 2017 W.H.O. classification of pituitary adenomas redefined null cell adenomas (NCAs) as negative for all adenohypophyseal hormones and the transcription factors (TFs) SF-1, PIT-1, and T-PIT, limited data exist characterizing these tumors1. We characterize NCAs in comparison to hormone negative adenomas (HNAs), which demonstrate negative hormone immunostaining in the context of positive TF immunoreactivity.
Methods: Retrospective review of 22 patients with HNAs between 2011-2019. Samples were stained for PIT-1 and SF-1. Negative ACTH staining served as a proxy for T-PIT given demonstrated prior concordance of these stains2. Demographics, tumor characteristics, preoperative symptoms, and postoperative outcomes were assessed.
Results: Fifteen samples (68%) stained negative for both PIT-1 and SF-1 and were classified as NCAs. Seven were positive for SF-1 (n=3), PIT-1 (n=3), or both (n=1) and were classified as HNAs. NCA patients were predominantly female (80%), while those with HNAs were predominantly male (57%). All tumors were macroadenomas, with mean maximal tumor diameter of 28mm in NCAs vs 23mm in HNAs (p=0.2705). NCAs were more likely to demonstrate suprasellar invasion (100% vs. 71%, p=0.0325), and although not statistically significant, cavernous sinus invasion (53% vs. 43%, p=0.6695), and higher MIB-1 proliferative index (2.271 vs. 1.971, p=0.733). The most common preoperative symptoms were headache (73% NCA, 71% HNA) and vision loss (53%, 40%). Postoperative improvements in headache (60% NCA, 71% HNA) and vision (53%, 50%) were comparable. Sixty-four percent of NCAs underwent gross total resection vs. 43% of HNAs (p=.3712). There were no recurrences or progressions in either group over 24mo. Few comparisons reached significance, potentially due to limited sample size.
Conclusion: A majority of HNAs demonstrated negative TF immunostaining and met criteria for NCAs. NCAs may be more common in females and demonstrate more suprasellar invasion than HNAs, but otherwise, do not vary significantly. TF staining may be of limited clinical utility in identifying high-risk pathology, however future studies with larger cohorts are warranted.
References:
1. Osamura RY, Lopes MBS, Grossman A, Matsuno A, Korbonits M, Trouillas J, Kovacs K (2017) Pituitary adenoma. In: Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) World health organization classification of tumours of endocrine organs, 4th edn. IARC, Lyon, pp 14-18.
2. Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N, Yamaguchi-Okadad M, Takeuchi Y, Yamada S (2015) The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Path 26(4):249-55.
Title: SUN-135 Characterization of Transcription Factor Immunostaining and Null Cell Adenoma Status in Hormone Negative Pituitary Adenomas
Description:
Abstract
Introduction: Since the 2017 W.
H.
O.
classification of pituitary adenomas redefined null cell adenomas (NCAs) as negative for all adenohypophyseal hormones and the transcription factors (TFs) SF-1, PIT-1, and T-PIT, limited data exist characterizing these tumors1.
We characterize NCAs in comparison to hormone negative adenomas (HNAs), which demonstrate negative hormone immunostaining in the context of positive TF immunoreactivity.
Methods: Retrospective review of 22 patients with HNAs between 2011-2019.
Samples were stained for PIT-1 and SF-1.
Negative ACTH staining served as a proxy for T-PIT given demonstrated prior concordance of these stains2.
Demographics, tumor characteristics, preoperative symptoms, and postoperative outcomes were assessed.
Results: Fifteen samples (68%) stained negative for both PIT-1 and SF-1 and were classified as NCAs.
Seven were positive for SF-1 (n=3), PIT-1 (n=3), or both (n=1) and were classified as HNAs.
NCA patients were predominantly female (80%), while those with HNAs were predominantly male (57%).
All tumors were macroadenomas, with mean maximal tumor diameter of 28mm in NCAs vs 23mm in HNAs (p=0.
2705).
NCAs were more likely to demonstrate suprasellar invasion (100% vs.
71%, p=0.
0325), and although not statistically significant, cavernous sinus invasion (53% vs.
43%, p=0.
6695), and higher MIB-1 proliferative index (2.
271 vs.
1.
971, p=0.
733).
The most common preoperative symptoms were headache (73% NCA, 71% HNA) and vision loss (53%, 40%).
Postoperative improvements in headache (60% NCA, 71% HNA) and vision (53%, 50%) were comparable.
Sixty-four percent of NCAs underwent gross total resection vs.
43% of HNAs (p=.
3712).
There were no recurrences or progressions in either group over 24mo.
Few comparisons reached significance, potentially due to limited sample size.
Conclusion: A majority of HNAs demonstrated negative TF immunostaining and met criteria for NCAs.
NCAs may be more common in females and demonstrate more suprasellar invasion than HNAs, but otherwise, do not vary significantly.
TF staining may be of limited clinical utility in identifying high-risk pathology, however future studies with larger cohorts are warranted.
References:
1.
Osamura RY, Lopes MBS, Grossman A, Matsuno A, Korbonits M, Trouillas J, Kovacs K (2017) Pituitary adenoma.
In: Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) World health organization classification of tumours of endocrine organs, 4th edn.
IARC, Lyon, pp 14-18.
2.
Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N, Yamaguchi-Okadad M, Takeuchi Y, Yamada S (2015) The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.
Endocr Path 26(4):249-55.
Related Results
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Abstract
Introduction
Carcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor that can lead to severe complications and carries a risk of distant metastasi...
Molecular pathogenesis of pituitary tumours
Molecular pathogenesis of pituitary tumours
Abstract
Pituitary adenomas are discovered in up to 25% of unselected autopsies, however, clinically apparent tumours are considerably less common. The pituitary gla...
Identification and gene expression profiling of human gonadotrophic pituitary adenoma stem cells
Identification and gene expression profiling of human gonadotrophic pituitary adenoma stem cells
Abstract
Background
Gonadotrophic pituitary adenoma is a major subtype of pituitary adenoma in the sellar region, but it is rarely involved in the h...
Neuroimaging Assessment of Aggressive Pituitary Adenomas
Neuroimaging Assessment of Aggressive Pituitary Adenomas
Aggressive pituitary adenomas (APA) are adenomas that show rapid growth, invasiveness, frequent or multiple relapses, or are resistant to conventional therapies. Clinical-imaging a...
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Abstract
Introduction
Fine-needle aspiration (FNA) is commonly used to investigate lymphadenopathy of suspected metastatic origin. The current study aims to find the association be...
Abstract 739: Increased mortality in patients with pituitary adenomas
Abstract 739: Increased mortality in patients with pituitary adenomas
Abstract
Purpose: To evaluate mortality rate and causes of death in patients with pituitary adenomas. Material & Methods: Five hundred seventy-two patients with ...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
GH secretion was reevaluated after completion of GH treatment at a mean age of 19.2 ± 3.2 yr in 35 young adults with childhood-onset GH deficiency (GHD). The patients were subdivid...

